Exclusive: Monsanto in talks with Bayer over confidentiality pact - source
Reuters
Published Jul 18, 2016 04:06PM ET
Exclusive: Monsanto in talks with Bayer over confidentiality pact - source
By Greg Roumeliotis
(Reuters) - U.S. seeds company Monsanto Co (N:MON) is negotiating the terms of a confidentiality agreement with Bayer AG (DE:BAYGn) that would allow extensive due diligence, after the German drug and crop chemical group raised its acquisition bid to more than $64 billion, a source familiar with the matter said on Monday.
While there is no certainty the latest talks between the two companies will result in a confidentiality pact, let alone in any deal, the move indicates that Bayer's latest offer may at least help the negotiations make progress.
Bayer said last week it had sweetened its acquisition offer for Monsanto to $125 per share in cash from $122 per share and offered it a $1.5 billion reverse antitrust breakup fee.
Monsanto would still require Bayer to raise its offer further in order to agree to a sale, the source said. The source asked not to be identified because the negotiations are confidential. Bayer and Monsanto declined to comment.
Monsanto shares jumped percent to $106.61 on the news. Bayer shares had previously ended trading in Frankfurt down 1.4 percent to 92.67 euros ($102.62).
Access to confidential information has been a major sticking point in Bayer's negotiations with Monsanto ever since the Leverkusen, Germany-based company first offered to acquire its smaller St. Louis, Missouri-based peer in May.
Monsanto Chief Executive Hugh Grant said last month that his company was in talks with Bayer and other companies in its sector about "alternative strategic options." He did not name the other companies, but Reuters has previously reported that Monsanto had discussed a business combination with BASF SE (DE:BAYGn).
Bayer argued last week that it had comprehensively addressed Monsanto's questions about financing and regulatory matters and said it was prepared to make certain commitments to regulators, if required, to complete a deal.
Monsanto responded by noting that its board would review Bayer's latest proposal, in consultation with its financial and legal advisers.
The seeds and agrochemicals industry, long dominated by six large companies, has been jolted by several large deals in the past year as low crop prices and belt-tightening by farmers pressured earnings.
Syngenta AG (S:SYNN), which Monsanto tried to buy last year, agreed in February to be acquired by ChemChina for $43 billion, while Dow Chemical (N:DOW) and DuPont (NYSE:DD) DD.N struck a $130 billion megamerger last year. ChemChina and Syngenta however are still waiting for the U.S. to clear their deal based on any national security concerns.
Get The News You Want
Bayer's relatively modest price increase in its offer last week also reflected the view that Monsanto's recent poor earnings have weighed on its valuation.
Monsanto said last month its net income tumbled more than 37 percent to $717 million in the quarter ended on May 31. It cited a global glut of generic glyphosate, the active ingredient in its Roundup herbicide, and delays in securing European Union import approval for its next-generation biotech soybeans.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.